Your browser doesn't support javascript.
loading
Taskforce recommends coordinated effort to improve clinical research conduct and find highly effective CFTR-directed treatment for rare mutations.
Solomon, G M; Nichols, D P.
Affiliation
  • Solomon GM; Department of Medicine, The Gregory Fleming James Cystic Fibrosis Research Center, University of Alabama at Birmingham, Birmingham, AL, USA.. Electronic address: msolomon@uab.edu.
  • Nichols DP; Department of Pediatrics, CF Therapeutics Development Network Coordinating Center, Seattle Children's Hospital, University of Washington, Seattle, WA, USA.
J Cyst Fibros ; 18(5): 579-580, 2019 09.
Article in En | MEDLINE | ID: mdl-31279576
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cystic Fibrosis Transmembrane Conductance Regulator / Cystic Fibrosis / Biomedical Research / Membrane Transport Modulators / Drug Discovery / Drug Development Type of study: Prognostic_studies Limits: Humans Country/Region as subject: Europa Language: En Journal: J Cyst Fibros Year: 2019 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cystic Fibrosis Transmembrane Conductance Regulator / Cystic Fibrosis / Biomedical Research / Membrane Transport Modulators / Drug Discovery / Drug Development Type of study: Prognostic_studies Limits: Humans Country/Region as subject: Europa Language: En Journal: J Cyst Fibros Year: 2019 Document type: Article